418 related articles for article (PubMed ID: 21537818)
21. Skin cancer in patients with psoriasis treated with coal tar. A 25-year follow-up study.
Pittelkow MR; Perry HO; Muller SA; Maughan WZ; O'Brien PC
Arch Dermatol; 1981 Aug; 117(8):465-8. PubMed ID: 7259240
[TBL] [Abstract][Full Text] [Related]
22. Low levels of emotional awareness predict a better response to dermatological treatment in patients with psoriasis.
Consoli SM; Rolhion S; Martin C; Ruel K; Cambazard F; Pellet J; Misery L
Dermatology; 2006; 212(2):128-36. PubMed ID: 16484819
[TBL] [Abstract][Full Text] [Related]
23. Plasma levels of p53 protein and chromosomal aberrations in patients with psoriasis treated with the Goeckerman regimen.
Borska L; Andrys C; Krejsek J; Hamakova K; Kremlacek J; Ranna D; Kotingova L; Fiala Z
Clin Exp Dermatol; 2009 Dec; 34(8):e881-3. PubMed ID: 20055855
[TBL] [Abstract][Full Text] [Related]
24. Angiogenic activity in patients with psoriasis is significantly decreased by Goeckerman's therapy.
Andrys C; Borska L; Pohl D; Fiala Z; Hamakova K; Krejsek J
Arch Dermatol Res; 2007 Mar; 298(10):479-83. PubMed ID: 17221216
[TBL] [Abstract][Full Text] [Related]
25. Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial.
Langley RG; Feldman SR; Han C; Schenkel B; Szapary P; Hsu MC; Ortonne JP; Gordon KB; Kimball AB
J Am Acad Dermatol; 2010 Sep; 63(3):457-65. PubMed ID: 20462664
[TBL] [Abstract][Full Text] [Related]
26. Low-dose, short-term ciclosporin (Neoral®) therapy is effective in improving patients' quality of life as assessed by Skindex-16 and GHQ-28 in mild to severe psoriasis patients.
Okubo Y; Natsume S; Usui K; Amaya M; Tsuboi R
J Dermatol; 2011 May; 38(5):465-72. PubMed ID: 21352289
[TBL] [Abstract][Full Text] [Related]
27. LCD plus NB-UVB reduces time to improvement of psoriasis vs. NB-UVB alone.
Bagel J
J Drugs Dermatol; 2009 Apr; 8(4):351-7. PubMed ID: 19363853
[TBL] [Abstract][Full Text] [Related]
28. Quality of life and cost of illness in patients with psoriasis in Malaysia: a multicenter study.
Tang MM; Chang CC; Chan LC; Heng A
Int J Dermatol; 2013 Mar; 52(3):314-22. PubMed ID: 23414155
[TBL] [Abstract][Full Text] [Related]
29. Frequency and magnitude of anxiety and depression in patients with psoriasis vulgaris.
Nasreen S; Ahmed I; Effendi S
J Coll Physicians Surg Pak; 2008 Jul; 18(7):397-400. PubMed ID: 18760060
[TBL] [Abstract][Full Text] [Related]
30. Retrospective analysis of a modified Goeckerman regimen for the treatment of psoriasis.
Cort DH; Schleider NR; Moskowitz RS; Horwitz SN; Frost P
Cutis; 1980 Feb; 25(2):201-3, 206-9. PubMed ID: 7357887
[TBL] [Abstract][Full Text] [Related]
31. Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigator-blinded pilot trial.
Gisondi P; Del Giglio M; Cotena C; Girolomoni G
Br J Dermatol; 2008 Jun; 158(6):1345-9. PubMed ID: 18410408
[TBL] [Abstract][Full Text] [Related]
32. Measuring quality of life of patients with different clinical types of psoriasis using the SF-36.
Sampogna F; Tabolli S; Söderfeldt B; Axtelius B; Aparo U; Abeni D;
Br J Dermatol; 2006 May; 154(5):844-9. PubMed ID: 16634884
[TBL] [Abstract][Full Text] [Related]
33. Comparison of Skindex-29, Dermatology Life Quality Index, Psoriasis Disability Index and Medical Outcome Study Short Form 36 in patients with mild to severe psoriasis.
Fernandez-Peñas P; Jones-Caballero M; Espallardo O; García-Díez A
Br J Dermatol; 2012 Apr; 166(4):884-7. PubMed ID: 22229951
[TBL] [Abstract][Full Text] [Related]
34. Utilization of narrow-band ultraviolet light B therapy and etanercept for the treatment of psoriasis (UNITE): efficacy, safety, and patient-reported outcomes.
Kircik L; Bagel J; Korman N; Menter A; Elmets CA; Koo J; Yang YC; Chiou CF; Dann F; Stevens SR;
J Drugs Dermatol; 2008 Mar; 7(3):245-53. PubMed ID: 18380206
[TBL] [Abstract][Full Text] [Related]
35. Successful use of a modified Goeckerman regimen in the treatment of chronic severe atopic dermatitis: A prospective pilot study.
Farahnik B; Beroukhim K; Danesh M; Nakamura M; Abrouk M; Zhu TH; Singh R; Lee K; Bhutani T; Koo J
J Am Acad Dermatol; 2016 Nov; 75(5):1068-1071. PubMed ID: 27745637
[No Abstract] [Full Text] [Related]
36. Costs and quality of life in patients with moderate to severe plaque-type psoriasis in Germany: a multi-center study.
Schöffski O; Augustin M; Prinz J; Rauner K; Schubert E; Sohn S; Reich K
J Dtsch Dermatol Ges; 2007 Mar; 5(3):209-18. PubMed ID: 17338796
[TBL] [Abstract][Full Text] [Related]
37. Goeckerman therapy versus biologics in the treatment of psoriasis.
Menter A
J Am Acad Dermatol; 2010 Mar; 62(3):516-7. PubMed ID: 20159322
[No Abstract] [Full Text] [Related]
38. Psoriasis has a major secondary impact on the lives of family members and partners.
Eghlileb AM; Davies EE; Finlay AY
Br J Dermatol; 2007 Jun; 156(6):1245-50. PubMed ID: 17459044
[TBL] [Abstract][Full Text] [Related]
39. A new coal tar preparation (Exorex).
Sarkar R; Thami GP; Kanwar AJ
Clin Exp Dermatol; 2001 Jul; 26(5):459-60. PubMed ID: 11488843
[No Abstract] [Full Text] [Related]
40. Role of depression in quality of life for patients with psoriasis.
Schmitt JM; Ford DE
Dermatology; 2007; 215(1):17-27. PubMed ID: 17587835
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
